Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Experimental treatment of brain metastases

Experimental treatment of brain metastases The rapid development of targeted therapies capable of entering the brain and the emerging technology of nano shells armed with cytotoxins reflects promising progress in the treatment of brain metastasis. The management of brain metastases is complicated by a number of major problems. The histological, molecular, biologic and immunologic nature of the various tumour types metastasizing to the brain differs significantly. As a consequence, the sensitivity towards various cytotoxic drugs or other treatment options varies substantially. Only few drugs are usually considered capable of penetrating the blood/brain and the brain/liquor barriers. Thus, the availability of a drug with adequate molecular size and pharmacokinetics within the compartments of the central nervous system determine the usage of cytotoxic drugs rather than the sensitivity of a specific tumour type to a specific drug. Recently, however, progress has been made in the development of more efficient types of therapy against brain metastases. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Experimental treatment of brain metastases

Loading next page...
 
/lp/springer-journals/experimental-treatment-of-brain-metastases-POt3oY9U84

References (22)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-008-0026-1
Publisher site
See Article on Publisher Site

Abstract

The rapid development of targeted therapies capable of entering the brain and the emerging technology of nano shells armed with cytotoxins reflects promising progress in the treatment of brain metastasis. The management of brain metastases is complicated by a number of major problems. The histological, molecular, biologic and immunologic nature of the various tumour types metastasizing to the brain differs significantly. As a consequence, the sensitivity towards various cytotoxic drugs or other treatment options varies substantially. Only few drugs are usually considered capable of penetrating the blood/brain and the brain/liquor barriers. Thus, the availability of a drug with adequate molecular size and pharmacokinetics within the compartments of the central nervous system determine the usage of cytotoxic drugs rather than the sensitivity of a specific tumour type to a specific drug. Recently, however, progress has been made in the development of more efficient types of therapy against brain metastases.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jan 1, 2008

There are no references for this article.